Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?

Warren Buffett has grown his empire by buying great companies. The CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing the exact same thing. Could that make him the next Buffett?

| More on:
The Motley Fool

One thing that Warren Buffett does very well is buy businesses. With the amount of capital that he has available to him through Berkshire Hathaway Inc., he can go out and buy out an entire company without blinking an eye.

And then when he does buy these companies, he is able to integrate them into the overall structure, and take the cash flow they provide to make even larger investments. This is how Buffett went from buying stocks—which he still does to an extent—to outright buying businesses.

Believe it or not, J. Michael Pearson, the CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing something quite similar. And Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant could be this generation’s Berkshire.

Ackman has invested 20% of his funds into Valeant. The reason he believes that he is holding a large stake in the next Berkshire is because of how many acquisitions Valeant makes every year. He views the company as a “platform company,” meaning it buys other companies to increase its own value. Instead of launching organic projects, it just buys them. That sounds a lot like Berkshire to me.

Over the past seven years Valeant has acquired over 100 businesses. And according to Ackman, they’ve been integrated into the larger organization rather seamlessly. If Pearson is good at one thing, it’s finding efficiency when combining companies.

Why this matters to you

Valeant isn’t slowing down. The company is going to continue buying other firms—large and small—with the goal of increasing its size. That’s how Berkshire works and that’s likely how Valeant is going to continue to work over the coming years.

This matters to you because platform companies are perpetually undervalued. Ackman has two examples to back this up. When the company bought Bausch & Lomb, the stock was valued at $74. The announcement of its agreement to buy made the price jump to $95. When it agreed to buy Salix Pharmaceuticals, the stock jumped from $217 to $250.

Now, there’s no denying that this stock has been on a meteoric rise. And Ackman’s belief is that the company will continue to make acquisitions in the $7-20 billion range every year. Pearson is not looking to create just another company; he wants to build a behemoth. And his strategy is to follow in the footsteps of the greatest investor of all time: Warren Buffett.

All of this, however, doesn’t immediately warrant a buy. Valeant is risky. It has a lot of debt and it doesn’t pay a penny in dividends to investors. Therefore, what you’re hoping for is a continuous rise in the price per share. In the event that the market corrects, this stock will drop because all stocks will drop.

But long term, if Pearson is successful and if Ackman can correctly predict the undervaluation of platform companies, then this stock will reward investors handsomely.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Plant growing through of trunk of tree stump
Investing

3 Canadian Growth Stocks to Buy Now While They’re on Sale

Let's dive into three of the top Canadian growth stocks long-term investors would do well to consider at this point…

Read more »

dividends grow over time
Energy Stocks

7.6% Dividend Yield! This Profit Generator Never Quits

Even as the energy sector stays volatile, this top Canadian energy stock shows how dependable infrastructure and operational strength could…

Read more »

top TSX stocks to buy
Dividend Stocks

3 Blue-Chip Dividend Stocks Every Canadian Should Own

These TSX blue-chip stocks have paid and increased their dividends for decades and are likely to sustain their payouts over…

Read more »

ways to boost income
Dividend Stocks

An 8.12%-Yield Dividend Stock That Could Benefit After Recent Bank of Canada Rate Cuts

Telus (TSX:T) stock is a dirt-cheap bargain after recent rate cuts, even amid considerable industry challenges.

Read more »

Close up of an egg in a nest of twigs on grass with RRSP written on it symbolizing a RRSP contribution.
Retirement

This Finance Stock Could Be the Cornerstone of Your RRSP

Sun Life Financial is a durable, global insurance growth stock that fits perfectly as an RRSP cornerstone, offering steady dividends…

Read more »

Printing canadian dollar bills on a print machine
Dividend Stocks

Investors: How to Turn $20K Into a Cash Flow Machine

$20,000 can become an income-yielding machine. Here's a four-stock portfolio that could earn nearly $950 a year in cash.

Read more »

Canadian Red maple leaves seamless wallpaper pattern
Metals and Mining Stocks

1 No-Brainer Canadian Stock to Buy and Hold Forever

Down over 22% from all-time highs, First Majestic is a TSX mining stock that offers you significant upside potential right…

Read more »

Silver coins fall into a piggy bank.
Retirement

It’s Not Too Late to Catch Up on Retirement Savings

It's never too late to save. Even saving and investing $50 a month can lead to serious wealth building in…

Read more »